1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmacokinetics Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmacokinetics Services Market, by Drug Type
8.1.1. Small Molecules Pharmacokinetics Services
8.1.1.1. Market Revenue and Forecast
8.1.2. Large Molecules (Biopharmaceuticals) Pharmacokinetics Services
8.1.2.1. Market Revenue and Forecast
9.1. Pharmacokinetics Services Market, by Service Type
9.1.1. Preclinical ADME and Human Studies
9.1.1.1. Market Revenue and Forecast
9.1.2. PK/PD Analysis and Reporting
9.1.2.1. Market Revenue and Forecast
9.1.3. Dosing Simulations
9.1.3.1. Market Revenue and Forecast
9.1.4. Risk Analysis and Others
9.1.4.1. Market Revenue and Forecast
10.1. Pharmacokinetics Services Market, by Therapeutic Application
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Cardiovascular Diseases
10.1.2.1. Market Revenue and Forecast
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Forecast
10.1.4. Autoimmune Diseases
10.1.4.1. Market Revenue and Forecast
10.1.5. Respiratory Disorders
10.1.5.1. Market Revenue and Forecast
10.1.6. Neurological Disorders
10.1.6.1. Market Revenue and Forecast
10.1.7. Others
10.1.7.1. Market Revenue and Forecast
11.1. Pharmacokinetics Services Market, by End User
11.1.1. Pharmaceutical & Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Research Organizations (CROs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Government Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Type
12.1.2. Market Revenue and Forecast, by Service Type
12.1.3. Market Revenue and Forecast, by Therapeutic Application
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Type
12.1.5.2. Market Revenue and Forecast, by Service Type
12.1.5.3. Market Revenue and Forecast, by Therapeutic Application
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Type
12.1.6.2. Market Revenue and Forecast, by Service Type
12.1.6.3. Market Revenue and Forecast, by Therapeutic Application
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Type
12.2.2. Market Revenue and Forecast, by Service Type
12.2.3. Market Revenue and Forecast, by Therapeutic Application
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Type
12.2.5.2. Market Revenue and Forecast, by Service Type
12.2.5.3. Market Revenue and Forecast, by Therapeutic Application
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Type
12.2.6.2. Market Revenue and Forecast, by Service Type
12.2.6.3. Market Revenue and Forecast, by Therapeutic Application
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Type
12.2.7.2. Market Revenue and Forecast, by Service Type
12.2.7.3. Market Revenue and Forecast, by Therapeutic Application
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Type
12.2.8.2. Market Revenue and Forecast, by Service Type
12.2.8.3. Market Revenue and Forecast, by Therapeutic Application
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Type
12.3.2. Market Revenue and Forecast, by Service Type
12.3.3. Market Revenue and Forecast, by Therapeutic Application
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Type
12.3.5.2. Market Revenue and Forecast, by Service Type
12.3.5.3. Market Revenue and Forecast, by Therapeutic Application
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Type
12.3.6.2. Market Revenue and Forecast, by Service Type
12.3.6.3. Market Revenue and Forecast, by Therapeutic Application
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Type
12.3.7.2. Market Revenue and Forecast, by Service Type
12.3.7.3. Market Revenue and Forecast, by Therapeutic Application
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Type
12.3.8.2. Market Revenue and Forecast, by Service Type
12.3.8.3. Market Revenue and Forecast, by Therapeutic Application
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Type
12.4.2. Market Revenue and Forecast, by Service Type
12.4.3. Market Revenue and Forecast, by Therapeutic Application
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Type
12.4.5.2. Market Revenue and Forecast, by Service Type
12.4.5.3. Market Revenue and Forecast, by Therapeutic Application
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Type
12.4.6.2. Market Revenue and Forecast, by Service Type
12.4.6.3. Market Revenue and Forecast, by Therapeutic Application
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Type
12.4.7.2. Market Revenue and Forecast, by Service Type
12.4.7.3. Market Revenue and Forecast, by Therapeutic Application
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Type
12.4.8.2. Market Revenue and Forecast, by Service Type
12.4.8.3. Market Revenue and Forecast, by Therapeutic Application
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Type
12.5.2. Market Revenue and Forecast, by Service Type
12.5.3. Market Revenue and Forecast, by Therapeutic Application
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Type
12.5.5.2. Market Revenue and Forecast, by Service Type
12.5.5.3. Market Revenue and Forecast, by Therapeutic Application
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Type
12.5.6.2. Market Revenue and Forecast, by Service Type
12.5.6.3. Market Revenue and Forecast, by Therapeutic Application
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Charles River Laboratories International, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eurofins Scientific SE
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Certara, L.P.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. IQVIA Holdings, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. LabCorp / Covance
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Evotec AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pacific BioLabs
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. GVK Biosciences Private Limited
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Shanghai Medicilon Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Parexel International Corporation
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
